MA33409B1 - Produits de recombinaisoon de casb7439 - Google Patents

Produits de recombinaisoon de casb7439

Info

Publication number
MA33409B1
MA33409B1 MA34476A MA34476A MA33409B1 MA 33409 B1 MA33409 B1 MA 33409B1 MA 34476 A MA34476 A MA 34476A MA 34476 A MA34476 A MA 34476A MA 33409 B1 MA33409 B1 MA 33409B1
Authority
MA
Morocco
Prior art keywords
casb7439
recombination products
methods
recombination
products
Prior art date
Application number
MA34476A
Other languages
Arabic (ar)
English (en)
Inventor
Normand Blais
Martine Harvey
Anthony Pilorget
Clément Rioux
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA33409B1 publication Critical patent/MA33409B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur des composés et des procédés pour l'augmentation de la production par recombinaison de polypeptides CASB7439 et sur leurs procédés d'utilisation.
MA34476A 2009-05-27 2010-05-25 Produits de recombinaisoon de casb7439 MA33409B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18138009P 2009-05-27 2009-05-27
US22039609P 2009-06-25 2009-06-25
PCT/EP2010/057141 WO2010136443A1 (fr) 2009-05-27 2010-05-25 Produits de recombinaison de casb7439

Publications (1)

Publication Number Publication Date
MA33409B1 true MA33409B1 (fr) 2012-07-03

Family

ID=42556967

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34476A MA33409B1 (fr) 2009-05-27 2010-05-25 Produits de recombinaisoon de casb7439

Country Status (19)

Country Link
US (1) US8916514B2 (fr)
EP (1) EP2435469A1 (fr)
JP (1) JP2012528106A (fr)
KR (1) KR20120014054A (fr)
CN (1) CN102459324B (fr)
AU (1) AU2010252012A1 (fr)
BR (1) BRPI1012078A2 (fr)
CA (1) CA2763486A1 (fr)
CL (1) CL2011002994A1 (fr)
CO (1) CO6400229A2 (fr)
DO (1) DOP2011000348A (fr)
EA (1) EA020617B1 (fr)
IL (1) IL216351A0 (fr)
MA (1) MA33409B1 (fr)
MX (1) MX2011012623A (fr)
NZ (1) NZ596501A (fr)
PE (1) PE20120400A1 (fr)
SG (1) SG176220A1 (fr)
WO (1) WO2010136443A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5615601A (en) 2000-02-23 2001-09-03 Smithkline Beecham Biolog Novel compounds
DE60131670T2 (de) * 2000-10-18 2008-10-30 Glaxosmithkline Biologicals S.A. Impfstoffe gegen Krebskrankheiten
US20140171626A1 (en) * 2012-12-19 2014-06-19 Glaxosmithkline Llc Protein purification
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520592D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2018055060A1 (fr) * 2016-09-21 2018-03-29 Amal Therapeutics Sa Fusion comprenant un peptide de pénétration cellulaire, un multi-épitope et un agoniste des peptides tlr pour le traitement du cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3724093A (en) 1992-02-18 1993-09-03 Smithkline Beecham Corporation Vaccinal polypeptides
AU8116494A (en) 1993-11-12 1995-06-13 Kenichi Matsubara Gene signature
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
CA2245545C (fr) 1996-02-09 2008-12-30 Smithkline Beecham Biologicals S.A. Produit vaccinal issu du gene 63 actif contre le virus varicelle-zona
DE69943359D1 (de) 1998-02-05 2011-05-26 Glaxosmithkline Biolog Sa Tumorassoziierte Antigenderivate der Mage-Familie, zur Herstellung von Fusionsproteinen mit T-Helper Epitope und Zusammensetzungen zur Impfung
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
HUP0101047A3 (en) 1998-03-09 2004-10-28 Smithkline Beecham Biolog Combined vaccine compositions
US6087168A (en) 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
DK1165778T3 (da) 1999-03-11 2007-02-12 Glaxosmithkline Biolog Sa Anvendelser af CASB618-polynukleotider og -polypeptider
AU5788900A (en) 1999-07-07 2001-01-22 Tularik Inc. Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides
AU2001236589A1 (en) 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
US7811574B2 (en) * 2000-02-23 2010-10-12 Glaxosmithkline Biologicals S.A. Tumour-specific animal proteins
AU5615601A (en) * 2000-02-23 2001-09-03 Smithkline Beecham Biolog Novel compounds
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
WO2002061085A2 (fr) 2000-10-31 2002-08-08 Ryan James W Fragments polynucleotidiques genomiques isoles a partir de la region p15 du chromosome 11
GB0104259D0 (en) 2001-02-21 2001-04-11 Smithkline Beecham Biolog Novel compounds
GB0111974D0 (en) * 2001-05-16 2001-07-04 Glaxosmithkline Biolog Sa Novel Compounds
JP2006512901A (ja) * 2002-08-29 2006-04-20 ジェネンテック・インコーポレーテッド Ａｃｈａｅｔｅ−Ｓｃｕｔｅ様−２ポリペプチドとそのコード化核酸並びに腫瘍の診断と治療のための方法
CA2662915A1 (fr) 2006-09-08 2008-03-13 Corixa Corporation Procedes, compositions, et kits de detection et de surveillance d'un cancer du colon
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy

Also Published As

Publication number Publication date
CO6400229A2 (es) 2012-03-15
US8916514B2 (en) 2014-12-23
DOP2011000348A (es) 2012-01-15
CL2011002994A1 (es) 2012-07-20
US20120070491A1 (en) 2012-03-22
MX2011012623A (es) 2011-12-14
KR20120014054A (ko) 2012-02-15
AU2010252012A1 (en) 2011-12-22
IL216351A0 (en) 2012-01-31
JP2012528106A (ja) 2012-11-12
CA2763486A1 (fr) 2010-12-02
EP2435469A1 (fr) 2012-04-04
CN102459324B (zh) 2014-07-09
BRPI1012078A2 (pt) 2019-09-24
NZ596501A (en) 2013-11-29
EA201190274A1 (ru) 2012-06-29
PE20120400A1 (es) 2012-05-04
SG176220A1 (en) 2011-12-29
WO2010136443A1 (fr) 2010-12-02
CN102459324A (zh) 2012-05-16
EA020617B1 (ru) 2014-12-30

Similar Documents

Publication Publication Date Title
MA33409B1 (fr) Produits de recombinaisoon de casb7439
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MX2011011925A (es) Anticuerpos triespecificos o tetraespecificos.
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
TN2011000673A1 (en) Bace inhibitors
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MX2011003473A (es) Composiciones para el cuidado bucal.
MA33423B1 (fr) Différentiation de cellules souches mésenchymateuses
FR2923364B1 (fr) Recipient pour produits cosmetiques
MY178926A (en) Bispecific anti-vegf/anti-ang-2 antibodies
MX2012006549A (es) Composiciones y metodos que comprenden variantes de proteasa.
DE602007012072D1 (de) Orantagonisten
PL2126020T3 (pl) Hydrofobowo modyfikowane polialkilenoiminy jako inhibitory przenoszenia barwnika
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
FR2923491B1 (fr) Utilisation de bacteries pour la production de sources de bioenergie
MX2011007101A (es) Composiciones de hidrolizados proteicos que tienen capacidad mejorada para liberar colecistocinina (cck).
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
MY156769A (en) Heat-aging-resistant polyamides
MX2009011648A (es) Componente estructural a base de un material ceramico.
MY161868A (en) Anti-bv8 antibodies and uses thereof
BR112012018402A2 (pt) "produto refratário com elevado teor de zircônio".
MY149433A (en) Nutritional compositions containing punicalagins
EP2590652A4 (fr) Compositions pharmaceutiques contenant de la vanoxérine
MX2009013921A (es) Material refractario sin forma, un proceso para producir un material refractario sin forma, humedo como la tierra, y al uso del material refractario sin forma.
MX2010009960A (es) Producto ceramico refractario y un moldeado asociado.